---
document_datetime: 2025-12-29 08:32:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/onpattro.html
document_name: onpattro.html
version: success
processing_time: 0.1137029
conversion_datetime: 2025-12-30 02:39:33.876603
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Onpattro

[RSS](/en/individual-human-medicine.xml/66905)

##### Authorised

This medicine is authorised for use in the European Union

patisiran Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Onpattro](#news-on)
- [More information on Onpattro](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Onpattro is a medicine used to treat nerve damage caused by hereditary transthyretin (hATTR) amyloidosis, a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves.

Onpattro is used in adult patients in the first two stages of the nerve damage (stage 1, when the patient is able to walk unaided, and stage 2, when the patient can still walk but needs help).

hATTR amyloidosis is rare, and Onpattro was designated an 'orphan medicine' (a medicine used in rare diseases) on 15 April 2011.

Onpattro contains the active substance patisiran.

Expand section

Collapse section

## How is Onpattro used?

Onpattro can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of patients with amyloidosis.

The medicine is available as a solution for infusion (drip) into a vein. The recommended dose is 300 micrograms per kilogram body weight once every 3 weeks.

To reduce the risk of infusion-related reactions, patients should be given corticosteroid medicines, paracetamol and medicines known as H1 and H2 blockers before receiving Onpattro. Patients should also take vitamin A supplements during treatment with Onpattro.

Onpattro may be given at home by a healthcare professional if the patient has had at least 3 infusions given in hospital without problems. For more information about using Onpattro, see the package leaflet or contact your doctor or pharmacist.

## How does Onpattro work?

In patients with hATTR amyloidosis, a protein called transthyretin which circulates in the blood is defective and breaks easily. The broken protein forms amyloid deposits in tissues and organs around the body, including around nerves, where it interferes with their normal functions.

The active substance in Onpattro, patisiran, is a 'small interfering RNA' (siRNA), a very short piece of synthetic genetic material that has been designed to attach to and block the genetic material of the cell responsible for producing transthyretin. This reduces production of defective transthyretin, thereby reducing the formation of amyloids and relieving the symptoms of hATTR amyloidosis.

## What benefits of Onpattro have been shown in studies?

In one main study involving 225 hATTR amyloidosis patients with stage 1 or 2 nerve damage, Onpattro was shown to be more effective than placebo (a dummy treatment) at slowing down the nerve damage caused by the disease.

The main measure of effectiveness was the change in the patients' nerve damage, as measured using a standard scale called 'mNIS+7', with scores ranging from 0 to 304 (a higher score indicates more severe nerve damage). After 18 months of treatment, the mNIS+7 score decreased on average by 6 points with Onpattro (from around 81 to around 75 points), indicating a slight improvement of the patients' condition. This compares with an increase on average by 28 points with placebo (from around 75 to around 101 points), indicating that nerve damage got worse in these patients.

## What are the risks associated with Onpattro?

The most common side effects with Onpattro (which may affect more than 1 in 10 people) are peripheral oedema (swelling, especially of the ankles and feet) and infusion-related reactions including pain, nausea (feeling sick), headache, tiredness, dizziness, cough and breathing problems, reddening of the skin, rapid heartbeat, low or high blood pressure and swelling of the face.

For the full list of side effects and restrictions with Onpattro, see the package leaflet.

## Why is Onpattro authorised in the EU?

Onpattro was shown to be effective at slowing down nerve damage in hATTR amyloidosis patients with stage 1 or stage 2 nerve damage; available data were not sufficient to assume a beneficial effect in stage 3 patients (those confined to a wheelchair). Regarding safety, the most serious side effects are infusion-related reactions and these can be managed with premedication and changes to infusion speed.

The European Medicines Agency therefore decided that Onpattro's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Onpattro?

The company that markets Onpattro will provide educational materials for doctors and patients with information about how to give the medicine safely when at home and how to manage side effects.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Onpattro have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Onpattro are continuously monitored. Side effects reported with Onpattro are carefully evaluated and any necessary action taken to protect patients.

## Other information about Onpattro

Onpattro received a marketing authorisation valid throughout the EU on 27 August 2018.

Onpattro : EPAR - Medicine overview

Reference Number: EMA/521473/2018

English (EN) (99.12 KB - PDF)

**First published:** 30/10/2018

[View](/en/documents/overview/onpattro-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-964)

български (BG) (124.74 KB - PDF)

**First published:**

30/10/2018

[View](/bg/documents/overview/onpattro-epar-medicine-overview_bg.pdf)

español (ES) (95.98 KB - PDF)

**First published:**

30/10/2018

[View](/es/documents/overview/onpattro-epar-medicine-overview_es.pdf)

čeština (CS) (123.84 KB - PDF)

**First published:**

30/10/2018

[View](/cs/documents/overview/onpattro-epar-medicine-overview_cs.pdf)

dansk (DA) (96.82 KB - PDF)

**First published:**

30/10/2018

[View](/da/documents/overview/onpattro-epar-medicine-overview_da.pdf)

Deutsch (DE) (98.82 KB - PDF)

**First published:**

30/10/2018

[View](/de/documents/overview/onpattro-epar-medicine-overview_de.pdf)

eesti keel (ET) (95.56 KB - PDF)

**First published:**

30/10/2018

[View](/et/documents/overview/onpattro-epar-medicine-overview_et.pdf)

ελληνικά (EL) (126.35 KB - PDF)

**First published:**

30/10/2018

[View](/el/documents/overview/onpattro-epar-medicine-overview_el.pdf)

français (FR) (99.1 KB - PDF)

**First published:**

30/10/2018

[View](/fr/documents/overview/onpattro-epar-medicine-overview_fr.pdf)

hrvatski (HR) (118.47 KB - PDF)

**First published:**

30/10/2018

[View](/hr/documents/overview/onpattro-epar-medicine-overview_hr.pdf)

italiano (IT) (95.85 KB - PDF)

**First published:**

30/10/2018

[View](/it/documents/overview/onpattro-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (127.62 KB - PDF)

**First published:**

30/10/2018

[View](/lv/documents/overview/onpattro-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (121.33 KB - PDF)

**First published:**

30/10/2018

[View](/lt/documents/overview/onpattro-epar-medicine-overview_lt.pdf)

magyar (HU) (118.06 KB - PDF)

**First published:**

30/10/2018

[View](/hu/documents/overview/onpattro-epar-medicine-overview_hu.pdf)

Malti (MT) (125.21 KB - PDF)

**First published:**

30/10/2018

[View](/mt/documents/overview/onpattro-epar-medicine-overview_mt.pdf)

Nederlands (NL) (96.61 KB - PDF)

**First published:**

30/10/2018

[View](/nl/documents/overview/onpattro-epar-medicine-overview_nl.pdf)

polski (PL) (122.26 KB - PDF)

**First published:**

30/10/2018

[View](/pl/documents/overview/onpattro-epar-medicine-overview_pl.pdf)

português (PT) (96.95 KB - PDF)

**First published:**

30/10/2018

[View](/pt/documents/overview/onpattro-epar-medicine-overview_pt.pdf)

română (RO) (121.16 KB - PDF)

**First published:**

30/10/2018

[View](/ro/documents/overview/onpattro-epar-medicine-overview_ro.pdf)

slovenčina (SK) (121.51 KB - PDF)

**First published:**

30/10/2018

[View](/sk/documents/overview/onpattro-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.63 KB - PDF)

**First published:**

30/10/2018

[View](/sl/documents/overview/onpattro-epar-medicine-overview_sl.pdf)

Suomi (FI) (95.43 KB - PDF)

**First published:**

30/10/2018

[View](/fi/documents/overview/onpattro-epar-medicine-overview_fi.pdf)

svenska (SV) (96.82 KB - PDF)

**First published:**

30/10/2018

[View](/sv/documents/overview/onpattro-epar-medicine-overview_sv.pdf)

Onpattro : EPAR - Risk-management-plan summary

English (EN) (1.11 MB - PDF)

**First published:** 30/10/2018

**Last updated:** 29/02/2024

[View](/en/documents/rmp-summary/onpattro-epar-risk-management-plan-summary_en.pdf)

## Product information

Onpattro : EPAR - Product Information

English (EN) (284.9 KB - PDF)

**First published:** 30/10/2018

**Last updated:** 25/03/2025

[View](/en/documents/product-information/onpattro-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-774)

български (BG) (438.94 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/bg/documents/product-information/onpattro-epar-product-information_bg.pdf)

español (ES) (392.95 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/es/documents/product-information/onpattro-epar-product-information_es.pdf)

čeština (CS) (422.62 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/cs/documents/product-information/onpattro-epar-product-information_cs.pdf)

dansk (DA) (358.87 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/da/documents/product-information/onpattro-epar-product-information_da.pdf)

Deutsch (DE) (387.47 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/de/documents/product-information/onpattro-epar-product-information_de.pdf)

eesti keel (ET) (348.14 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/et/documents/product-information/onpattro-epar-product-information_et.pdf)

ελληνικά (EL) (448.98 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/el/documents/product-information/onpattro-epar-product-information_el.pdf)

français (FR) (457.12 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/fr/documents/product-information/onpattro-epar-product-information_fr.pdf)

hrvatski (HR) (425.05 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/hr/documents/product-information/onpattro-epar-product-information_hr.pdf)

íslenska (IS) (365.19 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/is/documents/product-information/onpattro-epar-product-information_is.pdf)

italiano (IT) (419.66 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/it/documents/product-information/onpattro-epar-product-information_it.pdf)

latviešu valoda (LV) (420.82 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/lv/documents/product-information/onpattro-epar-product-information_lv.pdf)

lietuvių kalba (LT) (420.72 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/lt/documents/product-information/onpattro-epar-product-information_lt.pdf)

magyar (HU) (426.41 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/hu/documents/product-information/onpattro-epar-product-information_hu.pdf)

Malti (MT) (438.22 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/mt/documents/product-information/onpattro-epar-product-information_mt.pdf)

Nederlands (NL) (368.51 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/nl/documents/product-information/onpattro-epar-product-information_nl.pdf)

norsk (NO) (367.96 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/no/documents/product-information/onpattro-epar-product-information_no.pdf)

polski (PL) (454.34 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/pl/documents/product-information/onpattro-epar-product-information_pl.pdf)

português (PT) (298.48 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/pt/documents/product-information/onpattro-epar-product-information_pt.pdf)

română (RO) (352.86 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/ro/documents/product-information/onpattro-epar-product-information_ro.pdf)

slovenčina (SK) (442.55 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/sk/documents/product-information/onpattro-epar-product-information_sk.pdf)

slovenščina (SL) (432.42 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/sl/documents/product-information/onpattro-epar-product-information_sl.pdf)

Suomi (FI) (353.58 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/fi/documents/product-information/onpattro-epar-product-information_fi.pdf)

svenska (SV) (359.59 KB - PDF)

**First published:**

30/10/2018

**Last updated:**

25/03/2025

[View](/sv/documents/product-information/onpattro-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000248933 24/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Onpattro : All Authorised presentations

English (EN) (69.42 KB - PDF)

**First published:** 30/10/2018

[View](/en/documents/all-authorised-presentations/onpattro-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-586)

български (BG) (93.33 KB - PDF)

**First published:**

30/10/2018

[View](/bg/documents/all-authorised-presentations/onpattro-all-authorised-presentations_bg.pdf)

español (ES) (69.86 KB - PDF)

**First published:**

30/10/2018

[View](/es/documents/all-authorised-presentations/onpattro-all-authorised-presentations_es.pdf)

čeština (CS) (83.65 KB - PDF)

**First published:**

30/10/2018

[View](/cs/documents/all-authorised-presentations/onpattro-all-authorised-presentations_cs.pdf)

dansk (DA) (76.71 KB - PDF)

**First published:**

30/10/2018

[View](/da/documents/all-authorised-presentations/onpattro-all-authorised-presentations_da.pdf)

Deutsch (DE) (71.57 KB - PDF)

**First published:**

30/10/2018

[View](/de/documents/all-authorised-presentations/onpattro-all-authorised-presentations_de.pdf)

eesti keel (ET) (70.55 KB - PDF)

**First published:**

30/10/2018

[View](/et/documents/all-authorised-presentations/onpattro-all-authorised-presentations_et.pdf)

ελληνικά (EL) (94.51 KB - PDF)

**First published:**

30/10/2018

[View](/el/documents/all-authorised-presentations/onpattro-all-authorised-presentations_el.pdf)

français (FR) (69.95 KB - PDF)

**First published:**

30/10/2018

[View](/fr/documents/all-authorised-presentations/onpattro-all-authorised-presentations_fr.pdf)

hrvatski (HR) (86.41 KB - PDF)

**First published:**

30/10/2018

[View](/hr/documents/all-authorised-presentations/onpattro-all-authorised-presentations_hr.pdf)

íslenska (IS) (77.29 KB - PDF)

**First published:**

30/10/2018

[View](/is/documents/all-authorised-presentations/onpattro-all-authorised-presentations_is.pdf)

italiano (IT) (69.39 KB - PDF)

**First published:**

30/10/2018

[View](/it/documents/all-authorised-presentations/onpattro-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (90.06 KB - PDF)

**First published:**

30/10/2018

[View](/lv/documents/all-authorised-presentations/onpattro-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (87.8 KB - PDF)

**First published:**

30/10/2018

[View](/lt/documents/all-authorised-presentations/onpattro-all-authorised-presentations_lt.pdf)

magyar (HU) (80.1 KB - PDF)

**First published:**

30/10/2018

[View](/hu/documents/all-authorised-presentations/onpattro-all-authorised-presentations_hu.pdf)

Malti (MT) (91.03 KB - PDF)

**First published:**

30/10/2018

[View](/mt/documents/all-authorised-presentations/onpattro-all-authorised-presentations_mt.pdf)

Nederlands (NL) (71.52 KB - PDF)

**First published:**

30/10/2018

[View](/nl/documents/all-authorised-presentations/onpattro-all-authorised-presentations_nl.pdf)

norsk (NO) (71.12 KB - PDF)

**First published:**

30/10/2018

[View](/no/documents/all-authorised-presentations/onpattro-all-authorised-presentations_no.pdf)

polski (PL) (90.16 KB - PDF)

**First published:**

30/10/2018

[View](/pl/documents/all-authorised-presentations/onpattro-all-authorised-presentations_pl.pdf)

português (PT) (70.93 KB - PDF)

**First published:**

30/10/2018

[View](/pt/documents/all-authorised-presentations/onpattro-all-authorised-presentations_pt.pdf)

română (RO) (69.96 KB - PDF)

**First published:**

30/10/2018

[View](/ro/documents/all-authorised-presentations/onpattro-all-authorised-presentations_ro.pdf)

slovenčina (SK) (86.62 KB - PDF)

**First published:**

30/10/2018

[View](/sk/documents/all-authorised-presentations/onpattro-all-authorised-presentations_sk.pdf)

slovenščina (SL) (78.25 KB - PDF)

**First published:**

30/10/2018

[View](/sl/documents/all-authorised-presentations/onpattro-all-authorised-presentations_sl.pdf)

Suomi (FI) (53.82 KB - PDF)

**First published:**

30/10/2018

[View](/fi/documents/all-authorised-presentations/onpattro-all-authorised-presentations_fi.pdf)

svenska (SV) (72.47 KB - PDF)

**First published:**

30/10/2018

[View](/sv/documents/all-authorised-presentations/onpattro-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Onpattro Active substance patisiran sodium International non-proprietary name (INN) or common name patisiran Therapeutic area (MeSH) Amyloidosis, Familial Anatomical therapeutic chemical (ATC) code N07

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

## Authorisation details

EMA product number EMEA/H/C/004699

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Alnylam Netherlands B.V.

Antonio Vivaldistraat 150

Opinion adopted 26/07/2018 Marketing authorisation issued 27/08/2018 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Onpattro : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.56 KB - PDF)

**First published:** 25/03/2025

[View](/en/documents/procedural-steps-after/onpattro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Onpattro : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (216.84 KB - PDF)

**First published:** 06/12/2018

**Last updated:** 04/06/2024

[View](/en/documents/procedural-steps-after/onpattro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Onpattro-H-C-PSUSA-00010715-202208 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/187790/2023

English (EN) (124.09 KB - PDF)

**First published:** 02/06/2023

[View](/en/documents/scientific-conclusion/onpattro-h-c-psusa-00010715-202208-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Onpattro-H-C-PSUSA-00010715-202002 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/523806/2020

English (EN) (130.55 KB - PDF)

**First published:** 04/12/2020

[View](/en/documents/scientific-conclusion/onpattro-h-c-psusa-00010715-202002-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Onpattro-H-C-PSUSA-00010715-201908 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/273843/2020

English (EN) (160.42 KB - PDF)

**First published:** 04/06/2020

[View](/en/documents/scientific-conclusion/onpattro-h-c-psusa-00010715-201908-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Onpattro : Orphan maintenance assessment report (initial authorisation)

Reference Number: EMA/564536/2018

English (EN) (300.59 KB - PDF)

**First published:** 30/10/2018

[View](/en/documents/orphan-maintenance-report/onpattro-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Onpattro : EPAR - Public assessment report

Reference Number: EMA/554262/2018

English (EN) (4.14 MB - PDF)

**First published:** 30/10/2018

[View](/en/documents/assessment-report/onpattro-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Onpattro

Adopted

Reference Number: EMA/CHMP/482444/2018

English (EN) (69.22 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-onpattro_en.pdf)

#### News on Onpattro

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

[New medicine for hereditary rare disease](/en/news/new-medicine-hereditary-rare-disease) 27/07/2018

#### More information on Onpattro

- [EU/3/11/857 - orphan designation for treatment of transthyretin-mediated amyloidosis](/en/medicines/human/orphan-designations/eu-3-11-857)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 25/03/2025

## Share this page

[Back to top](#main-content)